Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?



To: Ken W who wrote (20095)11/6/2006 11:46:50 AM
From: GalirayoRespond to of 23958
 
LOL .. don't loose "sight" of the Big Picture.

Italian Undersecretary of State Lauds Collaboration


TORONTO--(MARKET WIRE)--Oct 23, 2006 -- On October 20, 2006, Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, together with University Campus Bio-Medico of Rome, Italy, hosted a symposium as an adjunct to the Canadian Diabetes Association Professional Conference and Annual Meetings in Toronto, Canada.

The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at generex.com 



To: Ken W who wrote (20095)11/7/2006 10:46:16 AM
From: Sergio HRead Replies (1) | Respond to of 23958
 
OISI

Guys, sales rose, but earnings were unchanged and the profit margin was slightly lower. Reason is the new product rollout. Next q. we'll get an indication of how well the new software is selling and we can decide if we want to keep this one longer.



To: Ken W who wrote (20095)3/12/2007 1:26:07 PM
From: Sergio HRead Replies (2) | Respond to of 23958
 
OISI...

Anyone still holding OISI?

Comments on report?


Copyright © 1995-2013 Knight Sac Media. All rights reserved.